Cocrystal Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cocrystal Pharma, Inc.
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. Meanwhile, the firm has also offered an update on the state of its injectables and transdermals business in the US, which is contingent on resolving deficiencies at its Moraiya plant.
- Drug Discovery Tools
- Other Names / Subsidiaries
- RFS Pharma, LLC
- Cocrystal Pharma, Inc
- Aero Pharmaceuticals, Inc., ISR de Mexico, S. de R. L. de C.V, Cocrystal Discovery Inc.